Skip to content

Trial · Interventional

CompletedNot applicableRegistry data

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

NCTNCT07297238 (opens ClinicalTrials.gov in a new tab)Other id2025-09-17
Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

  • Measures Semaglutide, does not give it. It appears in the eligibility rules.
  • Names Glucagon, does not test it. It appears in the description.

Overview

Status
Completed
Phase
Not applicable
Enrollment
20 participants (actual)
Sponsor
Jinling Hospital, China · Other
Design
Randomized · Single masking
Countries
1 country

China

Start
24 Jan 2026
Primary completion
27 May 2026
Completion
30 Jun 2026
First posted
22 Dec 2025
Last update posted
14 Jul 2026
Conditions
Short Bowel Syndrome (SBS) · Intestinal Failure

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20262027
  1. N/A

    Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

    NCT07297238

    24 Jan 2026 to 30 Jun 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.

Interventions

  • GLP-1 Receptor AgonistsDrug

Arms2

  • Experimental

    Experimental arm

    Participants received semaglutide as a subcutaneous injection (dosage form) at a dose of 0.25 mg (dosage) once weekly (frequency) for 28 days (duration).

  • No intervention

    Control arm

    received appearance-matched placebo plus standard care, no additional semaglutide intervention therapy

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Serum Biomarkers of Intestinal Barrier Function

    Time frame · the initiation of enrollment and upon completion of the 28-days treatment period

    Registry description

    Serum Citrulline（µmol/L）

Secondary outcomes(6)

  1. Intestinal absorption of nutrients (protein)

    Time frame · the initiation of enrollment and upon completion of the 28-days treatment period

    Registry description

    Intestinal nitrogen balance（Kjeldahl method for total nitrogen intake and excretion）

  2. Intestinal absorption of nutrients (carbohydrate)

    Time frame · the initiation of enrollment and upon completion of the 28-days treatment period

    Registry description

    Fecal carbohydrate（Fecal pH measurement and analysis of fermentable substrates for indirect assessment）

  3. Intestinal absorption of nutrients (fat)

    Time frame · the initiation of enrollment and upon completion of the 28-days treatment period

    Registry description

    Fat excretion rates（van de Kamer method for direct measurement of total fecal fat excretion）

  4. Nutritional status indicator

    Time frame · the initiation of enrollment and upon completion of the 28-days treatment period

    Registry description

    Serum albumin (g/L) level

  5. PN Liberation Rate

    Time frame · the initiation of enrollment and upon completion of the 28-days treatment period

    Registry description

    A 20% reduction in the weekly parenteral nutrition volume from baseline

  6. Quality of life score

    Time frame · the initiation of enrollment and upon completion of the 28-days treatment period

    Registry description

    Quality of life was assessed using the SF-36 score from the date of randomization until the end of the 4-week intervention weeks. SF-36 consists of eight dimensions, each of which is measured on a scale of 0-100, with higher scores indicating a better quality of life.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies4

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2016

7 results

The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.

Thazhath et al. 2016Diabetescited by 72

PMID 26470783DOI 10.2337/db15-0893PUB-26470783

Rights unknown7 results
Source linkSee results (7)

More studies

3 studies on this page

Indexing hint: Animal study · 2022

Liraglutide attenuates intestinal ischemia/reperfusion injury via NF-κB and PI3K/Akt pathways in mice.

Zou et al. 2022Life sciencescited by 28

PMID 36206837DOI 10.1016/j.lfs.2022.121045PUB-36206837

Full text at the publisher
Publisher page

PubMed tag: none · 2018

Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open-Label Pilot Study.

Hvistendahl et al. 2018JPEN. Journal of parenteral and enteral nutritioncited by 50

PMID 27875281DOI 10.1177/0148607116672265PUB-27875281

Full text at the publisher
Publisher page

PubMed tag: none · 2016

GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation.

Bang-Berthelsen et al. 2016Inflammatory bowel diseasescited by 97

PMID 27542128DOI 10.1097/mib.0000000000000847PUB-27542128

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 80 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Participants voluntarily provided written informed consent for this trial; * Aged 18 to 80 years, inclusive, regardless of gender; * With stable vital signs; * Diagnosis of SBS-IF, confirmed by existing medical/surgical records, receiving parenteral nutrition (PN) due to surgical resection of the small intestine (\<200 cm from the duodenojejunal flexure), and meeting one of the following criteria: * Colon continuity maintained without jejunal/ileal stoma (Type II or III); * Presence of a jejunostomy or ileostomy (Type I); * Expected requirement of PN for more than 4 weeks, with an average PN caloric intake ≥80%; * Ability to comply with the medication dosing and visit schedule; * Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively; * No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection; * No history of drug abuse; * Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants); * No participation in any other drug trials (including the investigational product in this study) within three months prior to enrollment. Exclusion Criteria: * Individuals who do not meet the inclusion criteria or are deemed ineligible by the investigator; * Poor general condition, inability to accurately describe symptoms, presence of severe infection, respiratory insufficiency, or other conditions that may hinder active cooperation; * History of allergic diseases, allergic constitution, or hypersensitivity to drugs structurally related to the investigational product; * Patients with malignancy at any site; * Those with psychiatric disorders, inability to cooperate, or impaired consciousness; * Patients with contraindications to the investigational drug (including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2); * Immunodeficiency, or current use of immunosuppressants or corticosteroids; * Immediate family members of the sponsor, investigator, or study staff directly involved in the trial; * Any other condition considered by the investigator as grounds for exclusion.

PepBank is a research reference. Talk to a doctor before you use any peptide.